Search

Your search keyword '"Visentin, Andrea"' showing total 20 results

Search Constraints

Start Over You searched for: Author "Visentin, Andrea" Remove constraint Author: "Visentin, Andrea" Publisher springer science and business media llc Remove constraint Publisher: springer science and business media llc
20 results on '"Visentin, Andrea"'

Search Results

1. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia

5. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL

6. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study

8. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

9. Incidental lymphomas in surgical pathology: diagnostic clues and clinical-pathological correlations

10. Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

11. A case of “double hit” mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib

12. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)

13. The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia

14. Mitochondrial apoptosis is induced by Alkoxy phenyl-1-propanone derivatives through PP2A-mediated dephosphorylation of Bad and Foxo3A in CLL

16. The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma

17. p66Shc deficiency enhances CXCR4 and CCR7 recycling in CLL B cells by facilitating their dephosphorylation-dependent release from β-arrestin at early endosomes

19. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

20. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

Catalog

Books, media, physical & digital resources